Interestingly, irinotecan plus PD-L1 mAb increased intratumor CD8+ T cells possibly via accelerating CD8+ T cell proliferation in lymph nodes and/or tumors, and the combination of irinotecan plus PD-L1 mAb showed stronger anti-tumor activity than did PD-L1 mAb alone. This evidence concerns the gene CD8A and neoplasm.